ES2356458B1 - Métodos y productos para genotipado in vitro de variaciones génicas humanas asociadas a reacciones adversas a fármacos. - Google Patents

Métodos y productos para genotipado in vitro de variaciones génicas humanas asociadas a reacciones adversas a fármacos. Download PDF

Info

Publication number
ES2356458B1
ES2356458B1 ES200901846A ES200901846A ES2356458B1 ES 2356458 B1 ES2356458 B1 ES 2356458B1 ES 200901846 A ES200901846 A ES 200901846A ES 200901846 A ES200901846 A ES 200901846A ES 2356458 B1 ES2356458 B1 ES 2356458B1
Authority
ES
Spain
Prior art keywords
genotyping
vitro
products
methods
chips
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200901846A
Other languages
English (en)
Other versions
ES2356458A1 (es
Inventor
Diego Tejedor Hernández
Antonio Martínez Martínez
Laureano Simón Buela
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Progenika Biopharma SA
Original Assignee
Progenika Biopharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progenika Biopharma SA filed Critical Progenika Biopharma SA
Priority to ES200901846A priority Critical patent/ES2356458B1/es
Publication of ES2356458A1 publication Critical patent/ES2356458A1/es
Application granted granted Critical
Publication of ES2356458B1 publication Critical patent/ES2356458B1/es
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6834Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Métodos y productos para genotipado in vitro de variaciones génicas humanas asociadas a reacciones adversas a fármacos.#El método de genotipado se basa en la combinación de un diseño experimental de DNA-chips de genotipado y en el desarrollo de un sistema secuencial de procesamiento e interpretación de los datos experimentales generados por dichos DNA-chips de genotipado basado en el aumento de la señal de hibridación, lo que garantiza unos elevados niveles de especificidad, sensibilidad y reproducibilidad de los resultados, que permiten que dichos DNA-chips puedan ser utilizados como herramientas fiables de diagnóstico genético clínico; en particular, en la detección de variaciones génicas, por ejemplo, polimorfismos o mutaciones génicas asociadas con la resistencia a tratamientos farmacológicos.
ES200901846A 2009-09-11 2009-09-11 Métodos y productos para genotipado in vitro de variaciones génicas humanas asociadas a reacciones adversas a fármacos. Expired - Fee Related ES2356458B1 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES200901846A ES2356458B1 (es) 2009-09-11 2009-09-11 Métodos y productos para genotipado in vitro de variaciones génicas humanas asociadas a reacciones adversas a fármacos.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200901846A ES2356458B1 (es) 2009-09-11 2009-09-11 Métodos y productos para genotipado in vitro de variaciones génicas humanas asociadas a reacciones adversas a fármacos.

Publications (2)

Publication Number Publication Date
ES2356458A1 ES2356458A1 (es) 2011-04-08
ES2356458B1 true ES2356458B1 (es) 2012-01-23

Family

ID=43778039

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200901846A Expired - Fee Related ES2356458B1 (es) 2009-09-11 2009-09-11 Métodos y productos para genotipado in vitro de variaciones génicas humanas asociadas a reacciones adversas a fármacos.

Country Status (1)

Country Link
ES (1) ES2356458B1 (es)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2356207C (en) * 1999-10-21 2012-10-09 Case Western Reserve University Gene expression profiling of inflammatory bowel disease

Also Published As

Publication number Publication date
ES2356458A1 (es) 2011-04-08

Similar Documents

Publication Publication Date Title
Martínez-Iglesias et al. DNA methylation in neurodegenerative and cerebrovascular disorders
Hillard et al. Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence
Dee et al. Epigenetic changes associated with different types of stressors and suicide
Guidotti et al. Toward the identification of peripheral epigenetic biomarkers of schizophrenia
BR112013026502A2 (pt) "métodos para detecção localizada de ácido nucleico em amostra de tecido, bem como matriz para uso na referida detecção de ácido nucleico e seu método de preparação ou produção".
Jiyipong et al. Bartonella species in small mammals and their potential vectors in Asia
BR112016006556A8 (pt) arranjo detectável e seu método de produção, sistema para diagnosticar uma doença, distúrbio ou condição, método para determinar estado de doença, distúrbio ou condição em um indivíduo, amostra in-vitro ou amostra ambiental e método livre de identificação para detectar um analito não identificado
BRPI1008936B8 (pt) método in vitro para detectar pré-disposição para ou diagnóstico e/ou prognóstico de fibrose hepática ou cirrose ocorrendo em um indivíduo humano
Gazali et al. Detection of SARS-CoV-2 spike protein D614G mutation by qPCR-HRM analysis
Klokkaris et al. An overview of epigenetic changes in the Parkinson’s disease brain
Kaforou et al. Host RNA signatures for diagnostics: an example from paediatric tuberculosis in Africa
WO2012034013A3 (en) Detection of rna-interacting regions in dna
MX2016012718A (es) Determinación de polimorfismos de un solo nucleótido útil para predecir la respuesta para rasagilina.
Lam et al. Clinical applications of molecular technologies in hematology
ES2356458B1 (es) Métodos y productos para genotipado in vitro de variaciones génicas humanas asociadas a reacciones adversas a fármacos.
Verney et al. Molecular detection of 7SL‐derived small RNA is a promising alternative for trypanosomosis diagnosis
Zerebinski et al. Progress in malaria genomic surveillance using long-read sequencing
Bonnetain Health related quality of life and endpoints in oncology
Mohamed et al. Clinical impact of ultra deep versus Sanger sequencing detection of minority mutations on HIV-1 drug resistance genotype interpretation after virological failure
Gareeva et al. Brain neurotransmitter systems gene Polymorphism: the Search for pharmacogenetic markers of efficacy of haloperidol in Russians and Tatars
Quan et al. A Chemical–Genetic Criterion for Identifying Disease Biomarkers
RU2015127016A (ru) Способ выявления РНК вируса гепатита Е в клинических образцах от людей и в образцах внешней среды
Berner et al. Paraphilia, sexual preference disorders. Diagnosis, etiology, epidemiology, treatment and prevention
Goharpey et al. Raven’s Coloured Progressive Matrices performance as a valid predictor of cognitive and motor delay in intellectual disability regardless of etiology
Lejon et al. Diagnostic tools for human African trypanosomiasis elimination and clinical trials: The DiTECT-HAT project

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2356458

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20120123

FD2A Announcement of lapse in spain

Effective date: 20210929